Literature DB >> 12153607

Effects of glucose, free fatty acids or arginine load on the GH-releasing activity of ghrelin in humans.

Fabio Broglio1, Andrea Benso, Cristina Gottero, Flavia Prodam, Silvia Grottoli, Francesco Tassone, Mauro Maccario, Felipe F Casanueva, Carlos Dieguez, Romano Deghenghi, Ezio Ghigo, Emanuela Arvat.   

Abstract

OBJECTIVE: Ghrelin, a 28 amino acid peptide purified from the stomach and showing a unique structure with an n-octanoyl ester in serine-3 residue, is a natural ligand of the GH secretagogue (GHS) receptor (GHS-R) and strongly stimulates GH secretion. In humans, ghrelin is more potent than growth hormone-releasing hormone (GHRH) and non-natural GHS such as hexarelin. Moreover, ghrelin shows a true synergism with GHRH, has no interaction with hexarelin and, similarly to non-natural GHS, is partially refractory to the inhibitory effect of exogenous somatostatin (SS). Despite this evidence, the mechanisms underlying the GH-releasing effect of ghrelin in humans have not been fully clarified.
SUBJECTS: To this aim we enrolled six normal young volunteers [age (mean +/- SEM) 28.9 +/- 3.1 year; body mass index 22.3 +/- 1.0 kg/m2). DESIGN AND MEASUREMENTS: In all subjects we studied the effects of glucose (OGTT, 100 g oral glucose at -45 min) or free fatty acids (FFA) load [lipid-heparin emulsion, Li-He, Intralipid 10% 250 ml + heparin 2500 U i.v. from -30 to +120 min] as well as of arginine (ARG, 0.5 g/kg infused from 0 to +30 min) on the GH response to human ghrelin (1.0 micro g/kg i.v. at 0 min) administration. These results were compared with those obtained by studying the effects of OGTT, Li-He and ARG on the GH response to GHRH-29 (1.0 micro g/kg i.v. at 0 min).
RESULTS: The GH response to ghrelin (auc 5452.4 +/- 991.3 micro g/l/h) was higher (P < 0.05) than that after GHRH (1519.4 +/- 93.3 micro g/l/h). The GH response to GHRH was inhibited by OGTT (450.7 +/- 81.1 micro g/l/h, P < 0.05) and almost abolished by Li-He (230.0 +/- 63.6 micro g/l/h, P < 0.05) while was markedly potentiated by ARG (2520.4 +/- 425.8 micro g/l/h, P < 0.05). The GH response to GHRH + ARG, however, was lower (P < 0.05) than that to ghrelin alone. The GH response to ghrelin was blunted by OGTT (2153.1 +/- 781.9 micro g/l/h, P < 0.05) as well as by Li-He (3158.8 +/- 426.7 micro g/l/h, P < 0.05) but these responses remained higher (P < 0.05) than that to GHRH alone. On the other hand, ARG did not modify the GH response to ghrelin (6324.3 +/- 1275.5 micro g/l/h). For GH 1 micro g/l = 2 mU/l.
CONCLUSIONS: In humans, ghrelin exerts a strong stimulatory effect on GH secretion which is partially refractory to the inhibitory effect of both glucose and FFA load and is not enhanced by ARG. These factors almost abolish and potentiate, respectively, the GH response to GHRH, at least partially, via modulation of hypothalamic SS release. Thus, our findings agree with the hypothesis that ghrelin as well as non-natural GHS acts, at least partially, by antagonizing SS activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12153607     DOI: 10.1046/j.1365-2265.2002.01595.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  12 in total

Review 1.  Leptin and ghrelin: what is the impact on pituitary function?

Authors:  Felipe F Casanueva; Carlos Dieguez
Journal:  Rev Endocr Metab Disord       Date:  2005-01       Impact factor: 6.514

Review 2.  Therapeutic potential of ghrelin in the treatment of heart failure.

Authors:  Noritoshi Nagaya; Kenji Kangawa
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  Central ghrelin regulates peripheral lipid metabolism in a growth hormone-independent fashion.

Authors:  Susana Sangiao-Alvarellos; María J Vázquez; Luis Varela; Rubén Nogueiras; Asish K Saha; Fernando Cordido; Miguel López; Carlos Diéguez
Journal:  Endocrinology       Date:  2009-07-16       Impact factor: 4.736

Review 4.  Clinical review: The human experience with ghrelin administration.

Authors:  Margaret C Garin; Carrie M Burns; Shailja Kaul; Anne R Cappola
Journal:  J Clin Endocrinol Metab       Date:  2013-03-26       Impact factor: 5.958

5.  Ghrelin in diabetes and metabolic syndrome.

Authors:  Leena Pulkkinen; Olavi Ukkola; Marjukka Kolehmainen; Matti Uusitupa
Journal:  Int J Pept       Date:  2010-04-27

6.  Euglycemic hyperinsulinemia, but not lipid infusion, decreases circulating ghrelin levels in humans.

Authors:  M Möhlig; J Spranger; B Otto; M Ristow; M Tschöp; A F H Pfeiffer
Journal:  J Endocrinol Invest       Date:  2002-12       Impact factor: 4.256

Review 7.  Obesity, growth hormone and exercise.

Authors:  Gwendolyn A Thomas; William J Kraemer; Brett A Comstock; Courtenay Dunn-Lewis; Carl M Maresh; Jeff S Volek
Journal:  Sports Med       Date:  2013-09       Impact factor: 11.136

8.  Allosteric modulation of ghrelin receptor signaling by lipids.

Authors:  Marjorie Damian; Maxime Louet; Antoniel Augusto Severo Gomes; Céline M'Kadmi; Séverine Denoyelle; Sonia Cantel; Sophie Mary; Paulo M Bisch; Jean-Alain Fehrentz; Laurent J Catoire; Nicolas Floquet; Jean-Louis Banères
Journal:  Nat Commun       Date:  2021-06-24       Impact factor: 14.919

Review 9.  Targeting the ghrelin receptor: orally active GHS and cortistatin analogs.

Authors:  Romano Deghenghi; Fabio Broglio; Mauro Papotti; Giampiero Muccioli; Ezio Ghigo
Journal:  Endocrine       Date:  2003-10       Impact factor: 3.925

Review 10.  Ghrelin and the endocrine pancreas.

Authors:  Fabio Broglio; Cristina Gottero; Andrea Benso; Flavia Prodam; Marco Volante; Silvia Destefanis; Carlotta Gauna; Giampiero Muccioli; Mauro Papotti; Aart Jan van der Lely; Ezio Ghigo
Journal:  Endocrine       Date:  2003-10       Impact factor: 3.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.